Antiphospholipid antibodies during infectious mononucleosis and their long term clinical significance |
| |
| Authors: | Eli Ben-Chetrit Yonit Wiener-Well Ayman Fadeela Dana G. Wolf |
| |
| Affiliation: | 1. Infectious Diseases Unit, Shaare Zedek Medical Center affiliated with the Hebrew University Hadassah Medical School, Jerusalem, Israel;2. Clinical Virology Unit, Hadassah Hospital, The Hebrew University Hadassah Medical School, Jerusalem, Israel;1. Department of Clinical Medicine, University of Bologna, Bologna, Italy;2. Operative Unit of Microbiology and Virology, Sant’Orsola-Malpighi Hospital, Bologna, Italy;3. Scientific Affairs, Abbott Diagnostici, Roma, Italy;1. Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands;2. Department of Otorhinolaryngology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands;3. Department of Otorhinolaryngology, Leiden University Medical Center, Leiden, The Netherlands;4. Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands;1. Pediatric Clinic 1, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;2. The Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer-Sheva, Israel;3. The Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel;4. Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;1. Department of Pathology and Laboratory Medicine, Albany Medical Center Hospital, Albany, New York, United States;2. Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, United States;3. Department of Surgery, Albany Medical College, Albany, New York, United States;1. Service de Gastroentérologie et Hépatologie, Fédération des Spécialités Digestives, Hôpital Edouard Herriot, Lyon, France;2. Service de Pharmacologie, Hôpital Edouard Herriot, Lyon, France;3. Clinique Universitaire de Néphrologie, CHU A Michallon, Grenoble, France;4. Service de Néphrologie, Transplantation et Immunologie Clinique, Hôpital Edouard Herriot, Lyon, France;5. Clinique Universitaire d’Hépatogastroentérologie et INSERM U823, CHU A Michallon, Grenoble, France |
| |
| Abstract: | BackgroundThe prevalence of antiphospholipid antibodies (aPLs) during acute Epstein-Barr virus (EBV) infection may be as high as 30–60%. The role of these autoantibodies in the development of antiphospholipid syndrome (APS) is not clear.ObjectiveTo investigate the prevalence, persistence and clinical significance of aPLs in a series of patients diagnosed with acute EBV infection.Study designA cohort of 94 patients aged 15 or older, recently diagnosed with acute EBV was retrieved. Serum samples obtained during diagnosis were tested for the presence of aPLs and anti-β2GP antibodies. Patients with positive sera for aPLs were assessed for the persistence of aPLs and the development of APS.ResultsThe prevalence of aPLs among 94 patients with acute EBV was 37.2%. Five of 27 available serum samples were also positive for anti-β2 glycoprotein (anti-β2GP) antibodies. Repeat testing for aPLs after a median of 21 months post acute infection (range 13–50 months) was performed in 17 of the 35 patients with positive aPL test. All 17 patients were found negative for aPL-IgG antibodies. Two of them had positive aPL-IgM antibodies and positive anti-β2GP antibodies. None of the patients who had positive aPLs experienced any manifestations of APS.ConclusionThe disappearance of aPLs in the majority of the patients after acute EBV infection, along with the absence of consistent clinical findings, suggests that the detection of aPLs during acute EBV is not associated with the development APS over time. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
